کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
3058295 | 1580290 | 2016 | 5 صفحه PDF | دانلود رایگان |
• Spinal dural arteriovenous fistula (SDAVF) is a treatable cause of myelopathy.
• SDAVF should be considered when perimedullary vessel flow voids are shown in MRI.
• Severe disability, extensive cord swelling, and treatment failure are related to poor prognosis.
Spinal dural arteriovenous fistula (SDAVF) is a relatively common acquired vascular malformation of the spinal cord. Assessment of a SDAVF is often difficult because of non-specific findings on non-invasive imaging modalities. Diagnosis of a SDAVF is often delayed, and some patients receive unnecessary treatment and treatment delays, often resulting in a poor outcome. The aim of this study was to characterize the clinical presentation, typical imaging findings, and long-term outcome of SDAVF. Forty patients (13 women, 27 men; mean age 58.18 ± standard deviation 14.75 years) who were treated at our hospital from June 1992 to March 2014 were retrospectively reviewed. We investigated the baseline characteristics, clinical presentation, imaging findings, treatment modalities, and outcome of the patients. The most common clinical presentation was a sensory symptom (80%), followed by motor weakness (70%), and sphincter dysfunction (62.5%). Roughly one-third (32.5%) of patients had a stepwise progression of fluctuating weakness and sensory symptoms, but the most common presentation was chronic progressive myelopathic symptoms (47.5%). Thirty-four patients (85%) had T2 signal change on the spinal cord MRI, indicative of cord edema. Thirty-eight patients had typical perimedullary vessel flow voids on T2-weighted MRI. Twenty-eight patients were treated with endovascular embolization, five patients underwent surgery, and four patients underwent both. Clinical outcome was determined by severity of initial deficit (p = 0.008), extent of cord edema (p = 0.010), treatment failure (p = 0.004), and a residual fistula (p = 0.017). SDAVF causes a treatable myelopathy, so early diagnosis and intervention is essential.
Journal: Journal of Clinical Neuroscience - Volume 26, April 2016, Pages 105–109